

# Real-world results of oesophageal protection from a temperature control device during left atrial ablation

Lisa W.M. Leung \*, Pavandeep Toor , Zaki Akhtar , Abhay Bajpai , Anthony Li , Manav Sohal, and Mark M. Gallagher 

Department of Cardiology, St George's University Hospitals NHS Foundation Trust, Blackshaw Road, London SW17 0QT, UK

Received 20 February 2023; accepted after revision 26 March 2023

Ablation-related oesophageal injury is an important cause of serious complications from ablations for atrial fibrillation (AF).<sup>1–3</sup> Methods of oesophageal protection originally started simply by reduction of ablation power and contact force and recent studies continue to show that refinement in ablation lesion application remains an important aspect of safeguarding against collateral injury.<sup>4–6</sup> However, these methods alone are limited as these run the risk of an inefficient procedure or ineffective lesion application. Alternative ablation methods or modalities have also been developed and advanced over recent years. Pulsed field ablation seems to provide effective ablation lesions whilst remaining tissue selective, but clinical evaluations are ongoing, whilst further experience is gained from this ablation modality.<sup>7</sup> Amongst these developments in ablation methods, tools, and technology, dedicated devices made or repurposed for oesophageal protection during left atrial ablations have also been explored.

Recent randomized trial evidence suggests that active control of local temperature can significantly reduce thermal injury to the oesophagus during left atrial ablation compared to standard care.<sup>8,9</sup> Other methods of oesophageal protection have been attempted. Detailed monitoring of oesophageal temperature to minimize local heating and deviation of the oesophagus away from the site of danger are both intuitively appealing and form the rationale for products that are marketed commercially, though unsupported by trial evidence.<sup>10</sup>

The IMPACT study showed that active thermal protection of the oesophagus by the ensoETM (Attune Medical, Chicago, IL, USA)<sup>8</sup> is effective in preventing oesophageal injury during radiofrequency ablation. This is a commercially available device used for body temperature control in a critical care setting and repurposed for oesophageal protection during left atrial ablations. Following the IMPACT trial, it is increasingly used in an off-licence manner in left atrial ablation procedures whilst a multicentre study is currently in progress (NCT04577859).

The ensoETM device is a multi-lumen orogastric probe made of medical-grade silicone, 73 cm in length and 1.2 cm outer diameter. The lumens are arranged to allow distilled water to be pumped into

and out of the probe in a closed-loop system. The method of use in clinical practice was previously described.<sup>11</sup> It is placed after induction of anaesthesia and after the use of *trans*-oesophageal echo, usually by the attending anaesthetist. The radio-opaque tip should be confirmed to lie well below the diaphragm on fluoroscopy. The proximal end of the probe is connected to a mobile console that sets the irrigated water at the desired temperature. A mouth guard is used to protect it from the teeth in the same manner as a *trans*-oesophageal echo probe. When irrigating, the volume of water in the probe at all times is 55 mL, and it flows at 2.4 L/min exerting a maximum pressure of 103 kPa. Leakage of water or blockage of flow is detected by the console and provokes an alarm. The purpose of this type of device is to heat extract and therefore limit or prevent local thermal tissue damage and avoid inflammatory processes that lead to fistula formation.

Device-related safety data in the USA are collected by subsidiary bodies of the Food and Drug Administration. The well-established Manufacturer and User Facility Device Experience (MAUDE) database and the Medical and Radiation Emitting Device Recalls database have more recently been supplemented by the more comprehensive Total Product Life Cycle (TPLC) database. In Europe, the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the Swissmedic records of Field Safety Corrective Actions (FSCA) in Switzerland fulfil a similar role. We sought to understand the safety of the ensoETM device when used in a real-world setting by reviewing these device databases. The TPLC database was the single most comprehensive database, incorporating pre- and post-market data.

A systematic search was made using all databases to identify:


- (1) All adverse events associated with devices used in oesophageal protection during AF ablation (using product names and codes) from the time period of 2015–2022, the period in which the ensoETM has been available.
- (2) All oesophageal injuries including atrio-oesophageal fistulas from cardiac ablation procedures within the same time period.

By reviewing the narrative of each event, duplicate and irrelevant reports were manually filtered from the list. The date of access was

\* Corresponding author: Tel: +44 2087253079. E-mail address: lleung@sgul.ac.uk

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)



26 January 2023 with last update on the database on 9 January 2023 on the ensoETMs used to determine device usage to the same date.

23 089 recorded complications or adverse events related to left atrial ablations were recorded from 2015 to 2022, of which 2.3% were related to oesophageal injury of some kind. Oesophageal injury ranged from oesophageal tears and haematomas to atrio-oesophageal fistulas. Atrio-oesophageal fistulas alone accounted for 1.8% of the total adverse events. There are no data on the total number of ablations performed during this same time period from all the centres that contributed to the databases used, but in the UK alone, it is estimated that over 10 000 AF ablations are performed in 2019, pre-COVID-19.<sup>12</sup>

Atrio-oesophageal fistulas were most often linked to the product codes denoting ablation catheters or generators rather than codes linked to protection devices. LPB, OAD, and OAE were the main ablation product codes, but each search yielded a different percentage of oesophageal injuries reflecting the dependence of the databases on manual input of data (Figure 1).

Most reports on cases complicated by an atrio-oesophageal fistula failed to disclose which oesophageal protection device was used, if any (Table 1). In those where there were details, the majority did have an oesophageal temperature monitoring probe ( $n = 80$ ). The details on which type of temperature monitoring probes were used during these cases of fistulas were even more limited. In a previous review of the medical literature involving temperature monitoring probes during left atrial ablations, eight different commercially available probes were found.<sup>10</sup> Of these, only three were listed in the adverse event reports. The most common one listed was the S-Cath, Circa Scientific, an S-shaped multi-sensor oesophageal temperature probe with insulated thermocouples and 12 electrodes. There were four fistula cases where a deviation device was used. Although not specified, there are only three known deviation devices that underwent some form of clinical use or investigation—the DV8, EsoSure and Esolution. The physical profile of these deviation devices and method of use were previously described.<sup>10</sup> The DV8 is a balloon retractor and the EsoSure involves nitinol stylets placed into a plastic tube within the oesophagus so that the tube takes the form of the pre-shaped stylet, which then deviates the oesophagus. The Esolution device (not yet available commercially) differs in that there are stacking plates that only enable the device to deviate the oesophagus medial-laterally and with a suctioning

component to overcome the trailing edge effect. There's no randomized evidence for this type of device as yet. From a search of the international databases to date, there have been no cases of atrio-oesophageal fistulas in 25 216 uses of the ensoETM for oesophageal protection during left atrial ablations.

Attune Medical (Chicago, IL, USA)'s registry identified that 25 216 ensoETMs were used for the purpose of oesophageal protection in left atrial ablations with over 39 000 devices used in total for all indications during the period of interest. No other manufacturer of a device intended for oesophageal protection responded to our request for the number of devices used during this period.

From the international databases, there were six complications or adverse events related to the ensoETM. None of the adverse events led to significant patient harm. The reports mostly detail improper use of the probe due to insufficient training of staff. As an example, an attempt to place the ensoETM when there was already an orogastric tube *in situ* or lack of use of a mouth guard, which caused damage to the ensoETM probe (and likely damage to the endotracheal tube) and a subsequent water leak. Although not yet appearing in the database search, there is one confirmed case of oesophago-pericardial fistula from 25 216 uses.<sup>13</sup>

From 2015 to 2022, there have been more than 20 000 uses of the ensoETM device for the purpose of left atrial ablations, but no reports of atrio-oesophageal fistula to date. Based on the recognized prevalence of this complication, 10–50 cases would have been expected. This is robust validation of the findings from the IMPACT study, in that controlling the oesophageal temperature via the ensoETM provides significant oesophageal protection.

Although there are clear limitations in review of these databases, it still yields important information on the safety of a device during its continuing use in clinical practice.

**Conflict of interest:** Dr. Leung previously received research support from Attune Medical (Chicago IL). Dr Gallagher has received research funding from Attune Medical, Medtronic and has acted as a consultant for Medtronic and for Cook Medical. All other authors have no conflicts of interest to declare.

## Data availability

Data are available on request to the corresponding editor.

**Table 1** Adverse events associated with left atrial ablation procedures with product codes LPB, OAD, and OAE denoting the ablation products from 2015 to 2022

Product code by ablation	Fistula (n, %)	Other oesophageal injury (n)	Total oesophageal injury (n, %)	Total adverse events	Protective device used	Oesophageal monitoring probe	Oesophageal temperature control device	Retractor	No details
LPB	282 (2.3)	56	338 (2.8)	12 260		73	0	3	206
OAD	58 (1.6)	20	78 (2.1)	3676		5	0	0	53
OAE	81 (1.1)	30	111 (1.6)	7153		2	0	1	78
Total	421 (1.8)	106	527 (2.3)	23 089		80	0	4	337
Device details <sup>a</sup>	S-Cath- Circa Scientific, Level 1 and ER 400-9 made by Smiths Medical; Esotherm/Sensitherm, Fiab								

A search was conducted for the number of atrio-oesophageal fistulas within that time period and if additional devices were used for oesophageal protection in these fistula cases. An attempt was made to review for which specific devices were used within the reported fistula cases, but results were limited.

<sup>a</sup>Most fistula cases reported in these databases lacked in-depth clinical information including the protective method used, whether that was limitation of ablation power or contact force or if a protective device was used. Of the oesophageal monitoring probes specified in the reports, only S-Cath by Circa Scientific was linked to six cases of fistulas. The rest were linked to other oesophageal injury; most remain unknown. There was no other device apart from the ensoETM, used for oesophageal temperature control. The listed deviation devices, DV8, EsoSure are the only devices known to have been available during 2015–2022, but these are not specifically described in the reports.

## References

- Loring Z, Holmes DN, Matsouaka RA, Curtis AB, Day JD, Desai N *et al.* Procedural patterns and safety of atrial fibrillation ablation. *Circ Arrhythm Electrophysiol* 2020;**13**:e007944.
- Kapur S, Barbhuiya C, Deneke T, Michaud GF. Oesophageal injury and atrioesophageal fistula caused by ablation for atrial fibrillation. *Circulation* 2017;**136**:1247–55.
- Gillinov AM, Pettersson G, Rice TW. Oesophageal injury during radiofrequency ablation for atrial fibrillation. *J Thorac Cardiovasc Surg* 2001;**122**:1239–40.
- Müller J, Nentwich K, Berkovitz A, Ene E, Sonne K, Zhuravlev V *et al.* Acute oesophageal safety and long-term follow-up of AI-guided high-power short-duration with 50 W for atrial fibrillation ablation. *Europace* 2023:eua0053. doi:10.1093/europace/euad053
- Chieng D, Segan L, Sugumar H, Al-Kaisey A, Hawson J, Moore BM *et al.* Higher power short duration vs. lower power longer duration posterior wall ablation for atrial fibrillation and oesophageal injury outcomes: a prospective multi-centre randomized controlled study (Hi-Lo HEAT trial). *Europace* 2023;**25**:417–24.
- Halbfass P, Wielandts JY, Knecht S, Le Polain de Waroux JB, Tavernier R, De Wilde D *et al.* Safety of very high-power short-duration radiofrequency ablation for pulmonary vein isolation: a two-centre report with emphasis on silent oesophageal injury. *Europace* 2022;**24**:400–5.
- Ekanem E, Reddy VY, Schmidt B, Reichlin T, Neven K, Metzner A *et al.* Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). *Europace* 2022;**24**:1256–66.
- Leung LW, Bajpai A, Zuberi Z, Li A, Norman M, Kaba RA *et al.* Randomized comparison of oesophageal protection with a temperature control device: results of the IMPACT study. *Europace* 2021;**23**:205–15.
- Leung LW, Akhtar Z, Elbatran AI, Bajpai A, Li A, Norman M *et al.* Effect of oesophageal cooling on ablation lesion formation in the left atrium: insights from ablation Index data in the IMPACT trial and clinical outcomes. *J Cardiovasc Electrophysiol* 2022;**33**:2546–57.
- Leung LWM, Akhtar Z, Sheppard MN, Louis-Auguste J, Hayat J, Gallagher MM. Preventing esophageal complications from atrial fibrillation ablation: a review. *Heart Rhythm O2*. 2021;**2**:651–64.
- Zagrodzky J, Gallagher MM, Leung LWM, Sharkoski T, Santangeli P, Tschabrunn C *et al.* Cooling or warming the esophagus to reduce esophageal injury during left atrial ablation in the treatment of atrial fibrillation. *J Vis Exp* 2020:e60733. doi:10.3791/60733
- National Institute for Health and Care Excellence (NICE). 2021. Atrial fibrillation: diagnosis and management. NG196. <https://www.nice.org.uk/guidance/ng196> (30 January 2023, date last accessed).
- Sanchez J, Woods C, Zagrodzky J, Nazari J, Singleton M, Schrickler A *et al.* Multicenter analysis of atrioesophageal fistula rates before and after adoption of active esophageal cooling during atrial fibrillation ablation. *medRxiv* 2023.02.21.23286267. <https://doi.org/10.1101/2023.02.21.23286267>